Convalescent plasma has shown to be beneficial for 35% of patients. This risk reduction figure - shown in chart below - is from data from expanded access program that was analyzed by FDAA for the emergency use authorization announced today.
Conversation
Replying to
To clarify, the data compared those given convalescent plasma with a high level of antibodies from COVID to those given plasma with low levels.
So 35% more patients survived by getting the higher antibodies convalescent plasma.
54
17
17
This is cretinous, and coming from an official FDA account app along and unacceptable
1
5
49
Show replies
Actually it’s a reduction in mortality from 11.9% to 8.7% if given in first 3 days versus after 4 days. No idea where you’re getting the statement that it’s beneficial for 35% of patients. I know you’re new, but the accuracy of your tweets matter.
6
69
568
Further, this wasn’t a study per se, it was analysis of “expanded access” patient data. No control arm. No placebo. And now with the EUA you will limit the numbers who will enroll in RCTs that could prove efficacy.
3
29
326
Show replies
Was this dichotomization pre-specified?
8
Are you late for your Fox News spot?
You have misunderstood the statistics.
Shame on you.
5
Focusing on relative risk reduction is deliberately deceptive.
2
32